Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has been given an average recommendation of “Hold” by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $7.28.

A number of brokerages have commented on KERX. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a report on Wednesday, July 12th. BidaskClub downgraded shares of Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Morgan Stanley reiterated an “equal weight” rating and issued a $7.00 target price (up from $4.00) on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. Maxim Group set a $9.00 target price on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, Cowen and Company reiterated a “market perform” rating on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th.

Shares of Keryx Biopharmaceuticals (KERX) traded up 0.43% during mid-day trading on Friday, reaching $6.95. 864,963 shares of the company traded hands. The firm has a 50 day moving average of $7.01 and a 200-day moving average of $6.55. The stock’s market capitalization is $825.31 million. Keryx Biopharmaceuticals has a 52 week low of $4.11 and a 52 week high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.60). The firm had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The business’s revenue for the quarter was up 62.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.42) earnings per share. On average, equities research analysts expect that Keryx Biopharmaceuticals will post ($1.23) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/24/keryx-biopharmaceuticals-inc-kerx-receives-consensus-rating-of-hold-from-analysts.html.

Several hedge funds have recently modified their holdings of KERX. Principal Financial Group Inc. grew its stake in shares of Keryx Biopharmaceuticals by 4.2% during the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 590 shares during the last quarter. OZ Management LP purchased a new stake in shares of Keryx Biopharmaceuticals during the first quarter worth about $109,000. Raymond James Financial Services Advisors Inc. grew its stake in shares of Keryx Biopharmaceuticals by 51.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 5,628 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Keryx Biopharmaceuticals during the first quarter worth about $141,000. Finally, Legal & General Group Plc grew its stake in shares of Keryx Biopharmaceuticals by 1.2% during the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 300 shares during the last quarter. Institutional investors and hedge funds own 65.19% of the company’s stock.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.